Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

被引：0
|
作者：
Tesfaye, Helen [1 ]
Htoo, Phyo Than T. [2 ]
Paik, Julie M. [2 ]
Zakoul, Heidi [2 ]
Schmedt, Niklas [3 ]
Deruaz-Luyet, Anouk [3 ]
Koeneman, Lisette [4 ]
Wexler, Deborah [5 ]
Patorno, Elisabetta [2 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol, Dept Med, Boston, MA USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Lilly Deutschland GmbH, Bad Homburg, Germany
[5] Harvard Med Sch, Massachusetts Gen Hosp, Div Endocrinol, Dept Med,MGH Diabet Ctr, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
59
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [21] Empagliflozin selected cardiovascular and safety outcomes in routine care: first results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J. M.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Sambevski, S.
    Bessette, L.
    Kulldorff, M.
    Schneeweiss, S.
    DIABETOLOGIA, 2019, 62 : S329 - S330
  • [22] Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
    Patorno, E.
    Pawar, A.
    Franklin, J. M.
    Najafzadeh, M.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Sambevski, S.
    Bessette, L. G.
    Kulldorff, M.
    Schneeweiss, S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 104
  • [23] Reduced healthcare utilization in patients using Empagliflozin: An interim analysis from the Empagliflozin comparative effectiveness and safety (EMPRISE) study
    Najafzadeh, Mehdi
    Pawar, Ajinkya
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Ustyugova, Anastasia
    Bessette, Lily G.
    Gautam, Nileesa
    Schneeweiss, Sebastian
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 223 - 224
  • [24] Effectiveness and Safety of Empagliflozin in Routine Care in Europe and East Asia: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Karasik, Avraham
    Lanzinger, Stefanie
    Tan, Elise C. H.
    Yabe, Daisuke
    Kim, Dae Jung
    Sheu, Wayne H-H
    Cohen, Cheli Melzer
    Holl, Reinhard W.
    Ha, Kyoung Hwa
    Nystrom, Thomas
    Niskanen, Leo K.
    Jensen, Majken Linnemann
    Kyaw, Moe H.
    Nunez, Julio
    DIABETES, 2021, 70
  • [25] Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from the empagliflozin comparative effectiveness and safety (EMPRISE) study
    Karasik, A.
    Lanzinger, S.
    Tan, E. Chia-Hui
    Yabe, D.
    JungKim, D.
    Sheu, W. H-H
    Melzer-Cohen, C.
    Holl, R. W.
    Ha, K.
    Nystrom, T.
    Niskanen, L.
    Jensen, M. Linnemann
    Kyaw, M. H.
    Nunez, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 229 - 230
  • [26] Retinopathy risk factors in patients with type 2 diabetes on liraglutide
    Mahzari, Moeber M.
    Alanazy, Abdulmalik M.
    Feroz, Zeeshan
    Almani, Khalid M.
    Alghamdi, Meshari A.
    Almadani, Abdulaziz S.
    Alzahrani, Majed K.
    Alibrahim, Ahmed R.
    Badri, Motasim
    MEDICINE, 2024, 103 (29)
  • [27] REDUCED HEALTHCARE UTILIZATION IN PATIENTS USING EMPAGLIFLOZIN: AN INTERIM ANALYSIS FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Najafzadeh, M.
    Pawar, A.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Ustyugova, A.
    Bessette, L. G.
    Gautam, N.
    Schneeweiss, S.
    Patorno, E.
    VALUE IN HEALTH, 2019, 22 : S161 - S161
  • [28] Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
    Langslet, Gisle
    Nystroem, Thomas
    Vistisen, Dorte
    Carstensen, Bendix
    Grip, Emilie Toresson
    Casajust, Paula
    Tskhvarashvili, Giorgi
    Hoti, Fabian
    Klement, Riho
    Karlsdotter, Kristina
    Tuovinen, Mikko
    Ofstad, Anne Pernille
    Lajer, Maria
    Shay, Christina
    Koeneman, Lisette
    Farsani, Soulmaz Fazeli
    Niskanen, Leo
    Halvorsen, Sigrun
    JOURNAL OF DIABETES RESEARCH, 2024, 2024
  • [29] Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Sambevski, Steven
    Bessette, Lily G.
    Kulldorff, Martin
    Schneeweiss, Sebastian
    DIABETES, 2019, 68
  • [30] Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo
    Tesfaye, Helen
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Jawaid, Dureshahwar
    Wexler, Deborah J.
    Glynn, Robert
    Koeneman, Lisette
    Luyet, Anouk Deruaz
    Paik, Julie
    Patorno, Elisabetta
    CIRCULATION, 2021, 144
12345